Further use of protein kinase N beta
AssigneeAtugen AG
InventorsAnke Klippel-Giese, Jorg Kaufmann
Life of this patent
Estimating the term…
Abstract
The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway.
Claims28
A method of treating a disease or pathological condition associated with dysregulation of the PI-3 kinase pathway, comprising administering to a subject suffering from said disease an effective amount of a composition that inhibits the activity of protein kinase N beta.
A method for identifying an agent suitable for treating a disease or pathological condition associated with dysregulation of the PI-3 kinase pathway, comprising
- contacting a test system comprising a protein having protein kinase N beta activity with a composition comprising a candidate compound, and determining if protein kinase N beta activity is reduced in the presence of said candidate compound.
A method for diagnosing a disease associated with a dysregulated PI-3 kinase pathway in a subject suspected of suffering from said disease, comprising measuring protein kinase N beta activity in a sample obtained from said subject and comparing said activity with a control level of activity, wherein an increase in protein kinase N beta activity indicates the presence of disease.
A method for determining the efficacy of a therapeutic treatment regimen in a subject, comprising:
- measuring protein kinase N beta activity in a first sample obtained from the subject, thereby generating an initial level;
- administering the treatment regimen to the subject;
- measuring protein kinase N beta activity in a second sample from the patient at a time following administration of the treatment regimen, thereby generating a test level;
- and
- comparing the initial and test levels, wherein a decrease in protein kinase N beta activity in the test level relative to the initial level indicates that the treatment regimen is effective in the patient.
A method for selecting test agents having a therapeutic effect in a subject, comprising:
- measuring protein kinase N beta activity in a first sample obtained from the subject, thereby generating a pre-treatment level;
- administering a test agent to the subject;
- measuring protein kinase N beta activity in a second sample from the patient at a time following administration of the test agent, thereby generating data for a test level;
- and
- comparing the pre-treatment level to the test level, wherein data showing no decrease in the test level relative to the pre-treatment level indicates that the test agent is not effective in the patient;
- and
- eliminating the test agent from further evaluation or study.
A pharmaceutical composition comprising at least one agent that inhibits the activity of protein kinase N beta and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.